IMINOXYTRIAZINES AS RADICAL GENERATORS
    1.
    发明申请
    IMINOXYTRIAZINES AS RADICAL GENERATORS 审中-公开
    作为辐射发生器的IMINOXYTRIAZINES

    公开(公告)号:WO2014064064A1

    公开(公告)日:2014-05-01

    申请号:PCT/EP2013/072006

    申请日:2013-10-22

    申请人: BASF SE

    摘要: Iminoxytriazine compounds of the formula (I), wherein n is 1 or 2; R 1 and R 2 independently of each other are hydrogen, NH 2 , NHR 5 , NR 5 R 6 , COR 5 , COOR 5 , CONH 2 , CONHR 5 , CONR 5 R 6 , CN, SR 5 , OR 5 , C 1 -C 18 alkyl, C 3 -C 12 cycloalkyl, C 6 -C 14 aryl or C 2 -C 14 heteroaryl, wherein said C 3 -C 12 cycloalkyl, C 6 -C 14 aryl or C 2 -C 14 heteroaryl is unsubstituted or substituted by one or more radicals selected from the group consisting of C 1 -C 12 alkyl, C 3 -C 12 -cycloalkyl, phenyl, halogen and C 1 -C 12 alkoxy, or R 1 and R 2 together with the C atom to which they are linked form a 4 to 12 membered carbocyclic or heterocyclic saturated or unsaturated ring which is unsubstituted or substituted by one or more radicals selected from the group consisting of C 1 -C 12 alkyl, C 3 -C 12 -cycloalkyl, phenyl, halogen and C 1 -C 12 alkoxy; R 3 is F, Cl, OH, OR, SH, SR 5 , NH 2 , NHR 5 , NR 5 R 6 or R 1 R 2 C=N-O-; wherein R 1 and R 2 in all groups R 1 R 2 C=N-O- in the compound of the formula I are identical or different; if n is 1, R 4 is F, Cl, OH, OR 5 , SH, SR 5 , NH 2 , NHR 5 , NR 5 R 6 or R 1 R 2 C=N-O-; wherein R 1 and R 2 in all groups R 1 R 2 C=N-O- in the compound of the formula I are identical or different; if n is 2, R 4 is a difunctional group derived from a diol, diamine, aminoalcohol or mercaptoalcohol; R 5 and R 6 independently of each other are C 1 -C 18 alkyl, C 3 -C 12 cycloalkyl, C 6 -C 14 aryl or C 2 -C 14 heteroaryl; are suitable as radical generating agents.

    摘要翻译: 式(I)的亚氨基三嗪化合物,其中n为1或2; R 1和R 2彼此独立地是氢,NH 2,NHR 5,NR 5 R 6,COR 5,COOR 5,CONH 2,CONHR 5,CONR 5 R 6,CN,SR 5,OR 5,C 1 -C 18烷基,C 3 -C 12环烷基,C 6 -C 14芳基或C 2 -C 14杂芳基 其中所述C 3 -C 12环烷基,C 6 -C 14芳基或C 2 -C 14杂芳基是未取代的或被一个或多个选自C 1 -C 12烷基,C 3 -C 12 - 环烷基,苯基,卤素和C 1 -C 12烷氧基的基团取代或被R 1和 R2与它们所连接的C原子一起形成4-12元碳环或杂环饱和或不饱和环,其未被取代或被一个或多个选自C 1 -C 12烷基,C 3 -C 12环烷基, 苯基,卤素和C 1 -C 12烷氧基; R3是F,Cl,OH,OR,SH,SR5,NH2,NHR5,NR5R6或R1R2C = N-O-; 其中式I化合物中所有基团R1R2C = N-O-中的R1和R2相同或不同; 如果n是1,R4是F,Cl,OH,OR5,SH,SR5,NH2,NHR5,NR5R6或R1R2C = N-O-; 其中式I化合物中所有基团R1R2C = N-O-中的R1和R2相同或不同; 如果n为2,则R4为衍生自二醇,二胺,氨基醇或巯基醇的双官能团; R 5和R 6彼此独立地是C 1 -C 18烷基,C 3 -C 12环烷基,C 6 -C 14芳基或C 2 -C 14杂芳基; 适合作为自由基产生剂。

    新規トリアジン誘導体
    2.
    发明申请
    新規トリアジン誘導体 审中-公开
    新的TRIAZINE DERIVATIVE

    公开(公告)号:WO2013133367A1

    公开(公告)日:2013-09-12

    申请号:PCT/JP2013/056266

    申请日:2013-03-07

    摘要: 【課題】新規なトリアジン誘導体の提供。 【解決手段】式(I)で示されるトリアジン誘導体またはその薬学的に許容される塩。(式中、R 1 は、置換基を有してもよいアリール基、置換基を有してもよい複素環、置換基を有してもよい複素環式縮合環、置換基を有してもよいアルキニル基を表し、R 2 は、水素原子、ハロゲン原子、置換基を有してもよい低級アルキル基、置換基を有してもよいアルコキシ基を表し、R 3 は、置換基を有してもよいアリール基、置換基を有してもよい複素環、置換基を有してもよい複素環式縮合環を表し、R 4 は、水素原子、置換基を有してもよい低級アルキル基、置換基を有してもよいアルコキシ基、置換基を有してもよいアミノ基、ハロゲン原子を表し、R 5 は、水素原子、置換基を有してもよい低級アルキル基を表すか、あるいはR 1 と結合を形成し、置換基を有することもある飽和もしくは不飽和の、5ないし6員環を形成することによって、多環性縮合環を形成してもよい。)

    摘要翻译: [问题]提供新型的三嗪衍生物。 [溶液]式(I)表示的三嗪衍生物或其药学上可接受的盐。 (式中,R 1表示可以具有取代基的芳基,可以具有取代基的杂环,可以具有取代基的杂环稠环或可以具有取代基的炔基; R2表示氢原子,卤素原子,可以具有取代基的低级烷基或 任选取代的烷氧基; R 3表示任选取代的芳基,任选取代的杂环或任选取代的杂环稠合环; R 4表示氢原子,任选取代的低级烷基,任选取代的烷氧基,任选取代的氨基 或卤素原子; R 5表示氢原子或任选取代的低级烷基,或者可选地,R 5可与R 1结合并形成任选取代的五元或六元饱和或不饱和环,由此形成多环稠合 环。)

    AZACYTOSINE ANALOGS AND DERIVATIVES
    5.
    发明申请
    AZACYTOSINE ANALOGS AND DERIVATIVES 审中-公开
    氮杂胞苷类似物和衍生物

    公开(公告)号:WO2006099132A1

    公开(公告)日:2006-09-21

    申请号:PCT/US2006/008588

    申请日:2006-03-10

    摘要: Compounds and compositions of azacytosine analogs and derivatives are provided. In one aspect of the invention, analogs or derivatives of decitabine and azacitidine are provided with modification at the 2-, 4-, or 6- position of the triazine ring, at the 1'-6' position of the ribose ring, or combinations thereof. Methods of using, synthesizing and manufacturing these analogs and derivatives are also provided. These compounds can be formulated into pharmaceutical compositions that can be used for treating any disease associated with aberrant DNA methylation, or a disease or condition that is sensitive to the treatment with decitabine or azacitidine, such as hematological disorders, tumors and cancers.

    摘要翻译: 提供了氮杂胞嘧啶类似物和衍生物的化合物和组合物。 在本发明的一个方面,地西他滨和阿扎胞苷的类似物或衍生物在三环环的2-,4-或6-位,核糖环的1'-6'位置或组合 它们。 还提供了使用,合成和制造这些类似物和衍生物的方法。 这些化合物可以配制成可用于治疗与异常DNA甲基化相关的任何疾病的药物组合物,或对于用地西他滨或阿扎胞苷(例如血液病症,肿瘤和癌症)治疗敏感的疾病或病症。

    SUBSTITUTED 2,4-DIAMINO-1,3,5-TRIAZINES
    6.
    发明申请
    SUBSTITUTED 2,4-DIAMINO-1,3,5-TRIAZINES 审中-公开
    取代的2,4-二氨基-1,3,5-三嗪

    公开(公告)号:WO99029677A1

    公开(公告)日:1999-06-17

    申请号:PCT/EP1998/007691

    申请日:1998-11-28

    摘要: The invention relates to novel substituted 2,4-diamino-1,3,5-triazines of formula (I) in which Q represents O (oxygen), S (sulfur), SO, SO2, NH or N(alkyl), R represents hydrogen or optionally substituted alkyl, R represents hydrogen, formyl or respective optionally substituted alkyl, alkyl carbonyl, alkoxycarbonyl or alkyl amino carbonyl, R represents respective optionally substituted alkyl or cycloalkyl, R represents hydrogen or alkyl, R represents hydrogen or alkyl, Ar represents optionally substituted aryl or heteroaryl, and Z represents hydrogen, cyano, halogen, or respective substituted alkyl, alkoxyl, alkoxycarbonyl, alkylthio, alkyl sulfinyl, alkyl sulfonyl, alkenyl, alkynyl or cycloalkyl. The invention also relates to a method and novel intermediate products, to the production thereof, and the application thereof as herbicides.

    摘要翻译: 本发明涉及新的取代,其中Q表示O(氧),S(硫),SO,SO 2,NH或N(烷基)的式(I)的2,4-二氨基-1,3,5-三嗪; [R <1>是氢或任选被取代的烷基,R <2>代表氢,表示甲酰基或代表各自任选被取代的烷基,烷基羰基,烷氧基羰基或烷基氨基羰基,R <3>在每种情况下任选被取代的烷基或环烷基,R <4>代表氢或烷基时,R <5>是氢或烷基,Ar代表任选取代的芳基或杂芳基,和Z是氢,氰基,卤素,或代表各自任选被取代的烷基,烷氧基,烷基羰基,烷氧基羰基 ,烷硫基,烷基亚磺酰基,烷基磺酰基,烯基,炔基或环烷基; 过程和它们的制备方法和它们作为除草剂的用途的新的中间体。

    DEUTERATED QUINOXALINE COMPOUNDS
    8.
    发明申请

    公开(公告)号:WO2018106916A1

    公开(公告)日:2018-06-14

    申请号:PCT/US2017/065111

    申请日:2017-12-07

    CPC分类号: C07D471/14 C07B59/002

    摘要: This invention relates to novel 2,3,6b,7,8,9,10,10a-octahydro-1 H -pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a serotonergic, dopaminergic, and glutamatergic modulator.